Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell LymphomaMatthew S. Davids, Constantine S. Tam, Craig A. Portell et al.|Journal of Clinical Oncology|2018Cited by 28
74 | A MULTICENTER PHASE II STUDY OF GLOFITAMAB PLUS POLATUZUMAB‐R‐CHP FOR PATIENTS WITH HIGH‐RISK DIFFUSE LARGE B‐CELL LYMPHOMAJennifer L. Crombie, Juan Pablo Alderuccio, Oreofe O. Odejide et al.|Hematological Oncology|2025Cited by 3
Glofitamab and obinutuzumab (GLOBIN) as first-line therapy for patients with high-tumor burden follicular lymphoma: First results of a multicenter phase II trialReid W. Merryman, Joshua Brody, Gottfried von Keudell et al.|Blood|2025Cited by 0